Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients

Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts

(2013) B M Syed et al.   BRITISH JOURNAL OF CANCER

Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?

(2012) I. Vaz-Luis et al.   ANNALS OF ONCOLOGY

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement

(2012) S. Guiu et al.   ANNALS OF ONCOLOGY

Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype

(2012) Brenda Deyarmin et al.   ANNALS OF SURGICAL ONCOLOGY

Stage-specific breast cancer incidence rates among participants and non-participants of a population-based mammographic screening program

(2012) Solveig Hofvind et al.   BREAST CANCER RESEARCH AND TREATMENT

Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer

(2012) Naoki Hayashi et al.   BREAST CANCER RESEARCH AND TREATMENT

Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions

(2012) Isabelle Soerjomataram et al.   LANCET

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

St. Gallen 2011: Summary of the Consensus Discussion

(2011) Michael Gnant et al.   Breast Care

Joint effects of nulliparity and other breast cancer risk factors

(2011) S Opdahl et al.   BRITISH JOURNAL OF CANCER

HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods

(2011) J. M. S. Bartlett et al.   JOURNAL OF CLINICAL PATHOLOGY

The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment

(2011) Anthony S.-Y. Leong et al.   PATHOBIOLOGY

Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study

(2010) Shaheenah Dawood et al.   BREAST CANCER RESEARCH AND TREATMENT

HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma

(2010) Colin A Purdie et al.   HISTOPATHOLOGY

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

(2010) Fiona M. Blows et al.   PLOS MEDICINE

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

(2009) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival

(2009) S J Dawson et al.   BRITISH JOURNAL OF CANCER

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

CK5 Is More Sensitive Than CK5/6 in Identifying the “Basal-like” Phenotype of Breast Carcinoma

(2008) Rohit Bhargava et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

HER2 testing in the UK: further update to recommendations

(2008) R A Walker et al.   JOURNAL OF CLINICAL PATHOLOGY